XORTX’s board of directors accepted the resignation of the Former Auditor, as of January 16, 2025 and appointed the Successor Auditor as the new auditor of the Company effective January 16, 2025, and ...
FOR centuries, gout has been a deeply misunderstood disease, associated only with jolly, indulgent, and often big men. When Henry VIII was diagnosed, it became firmly entrenched in popular belief ...
Gout flares among adults in the United States are significantly underreported to healthcare providers, with nearly 72% of flares either not reported or pretreated/prevented by patients, according to ...
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. The company is actively involved in creating ...
XORTX Therapeutics (XRTX) announces the launch of a new late stage program to treat gout. The new drug development program – XRx-026 – will ...
XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...
and tolerability of serum uric acid lowering and maintenance with febuxostat in patients with gout. Febuxostat Open-label Clinical Trial of Urate-lowering Efficacy and Safety Adverse events were ...
Add articles to your saved list and come back to them any time. Teenage sprint sensation Gout Gout will pocket more than $6 million from adidas in a lucrative multi-year deal with the sporting ...
Diet to keep high uric acid levels in check (Freepik, representational image) Gout is a form of arthritis characterised by sudden and severe pain, redness, and swelling in the joints, often caused ...
Achieving serum urate to below 6 mg/dL with urate-lowering therapy (ULT) in patients with gout and chronic kidney disease (CKD) stage III is not linked to an increased risk for severe or end-stage ...